| Title: |
High frequency of potential interactions between direct‐acting antivirals and concomitant therapy in HIV/hepatitis C virus‐coinfected patients in clinical practice |
| Authors: |
Macías, J; Monge, P; Mancebo, M; Merchante, N; Neukam, K; Real, LM; Pineda, JA |
| Contributors: |
Instituto de Salud Carlos III; Federación Española de Enfermedades Raras |
| Source: |
HIV Medicine ; volume 18, issue 7, page 445-451 ; ISSN 1464-2662 1468-1293 |
| Publisher Information: |
Wiley |
| Publication Year: |
2016 |
| Collection: |
Wiley Online Library (Open Access Articles via Crossref) |
| Description: |
Objectives The aim of the study was to analyse the frequency and degree of potential drug−drug interactions ( DDI s) between direct‐acting antivirals ( DAA s) and concomitant medication used by HIV /hepatitis C virus ( HCV )‐coinfected patients, including antiretroviral therapy ( ART ) and other drugs. Methods All patients with HIV infection and viraemic HCV genotype 1, 3 or 4 coinfection attending a tertiary care centre in Spain (November 2014 to November 2015) were included in the study. DDI s were classified as major, i.e. drugs should not be co‐administered, or minor, i.e. close monitoring, dosage alteration or change in timing may be required if drugs are co‐administered, following the http://www.hep-druginteractions.org database recommendations. Results A total of 244 patients were included in the study, of whom 224 (92%) were previous injecting drug users. Major DDI s were found for: paritaprevir‐r/ombitasvir plus dasabuvir (3D), in 60 (44%) of 138 individuals with genotype 1; paritaprevir‐r/ombitasvir (2D), in 22 (37%) of 60 individuals with genotype 4; sofosbuvir/ledipasvir ( SOF / LDV ), in four (2%) of 198 patients with genotype 1 or 4; simeprevir ( SMV ) plus SOF , in 160 (81%) of 198 patients with genotype 1 or 4; daclatasvir ( DCV ) plus SOF , in seven (3%) of 244 patients with genotype 1, 3 or 4 ( P < 0.001). Minor DDI s were found for: 3D, in 123 (89%) individuals with genotype 1; 2D, in 52 (87%) individuals with genotype 4; SOF / LDV , in 154 (78%) patients with genotype 1 or 4; SMV plus SOF , in 129 (65%) patients with genotype 1 or 4; DCV plus SOF , in 149 (61%) patients with genotype 1, 3 or 4 ( P < 0.001). Conclusions Drug−drug interactions between DAA s and ART or other commonly prescribed medications are frequently found among HIV / HCV ‐coinfected patients. Potential major and minor DDI s are more frequent with 3D, 2D and SMV plus SOF regimens. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1111/hiv.12471 |
| Availability: |
http://dx.doi.org/10.1111/hiv.12471; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fhiv.12471; https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.12471 |
| Rights: |
http://onlinelibrary.wiley.com/termsAndConditions#vor |
| Accession Number: |
edsbas.24F0B4B |
| Database: |
BASE |